UGT1A1 and metabolic dysfunction-associated steatotic liver disease: When patients with NAFLD come out the increased serum TB and UGT1A1 levels, a severe steatosis of progression might be occurred, which can guide the clinical surveillance and treatment of patients with NAFLD.